113118-81-3

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-3-pyridinecarboxaldehyde is used as a key intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its unique chemical structure allows for the creation of a wide range of compounds with potential medicinal properties.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Bromo-3-pyridinecarboxaldehyde serves as an essential intermediate in the production of agrochemicals, such as pesticides and herbicides. Its involvement in the synthesis of these compounds helps to improve crop protection and yield.
Used in Fine Chemicals Industry:
5-Bromo-3-pyridinecarboxaldehyde is utilized as a crucial building block in the synthesis of fine chemicals, which are high-purity chemicals used in various applications, including fragrances, dyes, and specialty chemicals. Its versatility in chemical reactions enables the production of a diverse array of fine chemicals.
Used in Organic Chemistry Research:
As a significant reagent in organic chemistry research, 5-Bromo-3-pyridinecarboxaldehyde is employed in various chemical reactions and experiments. Its unique properties and reactivity make it an indispensable tool for researchers in the field of organic chemistry, aiding in the discovery and understanding of new chemical compounds and reactions.

InChI:InChI=1/C6H4BrNO/c7-6-1-5(4-9)2-8-3-6/h1-4H

Upstream product

• 39620-02-5 5-bromonicotinoyl chloride 
• 37669-64-0 (5-bromopyridin-3-yl)methanol 
• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 
• 500-22-1 3-pyridinecarboxaldehyde 
• 98555-51-2 5-Bromo-pyridine-2,3-dicarboxylic acid 
• 624-28-2 2,5-dibromopyridine 
• 693-04-9 butyl magnesium bromide 
• 79-37-8 oxalyl dichloride 
• 342013-81-4 4-[(5-bromopyridin-3-yl)carbonyl]morpholine 
• 68-12-2 N,N-dimethyl-formamide 
• 110619-11-9 3-bromo-1-(phenoxycarbonyl)-1,2-dihydropyridine 
• 626-55-1 3-Bromopyridine 
• 112193-41-6 5-bromonicotinic acid hydrazide 
• 20986-40-7 ethyl 5-bromo-3-pyridinecarboxylate 

Downstream Products

• 908864-98-2 1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine 
• 108337-85-5 2,6-dimethyl-4-(5-bromo-3-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester 
• 73335-64-5 1-(5-bromopyridin-3-yl)-N-methylmethanamine 
• 906004-07-7 (S)-4-(5-bromo-pyridin-3-ylmethyl)-3-(4-fluoro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 183608-59-5 3-bromo-5-[(pyrrolidin-1-yl)methyl]pyridine 
• 113118-84-6 5-phenyl-3-pyridinecarboxaldehyde 
• 927696-11-5 5-[3-(2-Methoxy-phenyl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-pyridine-3-carbaldehyde 
• 342601-30-3 3-formyl-5-(3-thiophene)pyridine 
• 1255871-66-9 N-((5-bromopyridin-3-yl)(4-fluorophenyl)methyl)ethanesulfonamide 
• 1255870-88-2 2-fluoro-4-(5-formyl-pyridin-3-yl)-benzonitrile 
• 1255871-11-4 4-(5-formylpyridin-3-yl)benzonitrile 
• 1343455-30-0 2-[5-(4-tert-butyl-phenyl)-pyridin-3-yl]-3,3-dimethyl-1,2,3,4-tetrahydro-quinoline-6-carboxylic acid 
• 1343455-37-7 2-[5-(4-tert-butyl-phenyl)-pyridin-3-yl]-3,3-dimethyl-1,2,3,4-tetrahydro-quinoline-6-carboxylic acid ethyl ester 
• 1391609-84-9 2-{5-[4-(2,4-dimethyl-phenyl)-piperazin-1-yl]-pyridin-3-yl}-4,4-dimethyl-1,2,3,4-tetrahydro-quinoline-6-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Synthesis of (±) [5-3H] N′-nitrosoanatabine, a tobacco-specific nitrosamine

Tobacco-specific N′-nitrosamines (TSNA) are a unique class of systemic organ-specific carcinogens. The TSNA are formed by N-nitrosation of nicotine and of the minor tobacco alkaloids after harvesting of tobacco and during smoking. The N-nitrosation of anatabine leads to N′-nitrosoanatabine (NAT; 1-nitroso-1,2,3,4-tetrahydro-2,3′-bipyridyl) which requires in-depth assays in laboratory animals other than the rat. Furthermore, delineation of its tissue distribution and metabolism is needed for structure: activity comparisons with other TSNA and for the assessment of potential human risk from this TSNA. We have, therefore, synthesized (±)[5-3 H]NAT. 5-Bromo-3-pyridine-carboxaldehyde was condensed with ethyl carbamate prior to Diels-Alder reaction with 1,4-butadiene to give the racemic anatabine ring system. Hydrolysis, followed by reduction with LiA1T4 and nitrosation, led to (±) [5-3H]NAT (60% yield, specific activity 266 mCi/mmol, radiochemical purity of > 99%). Copyright

Catalytic asymmetric synthesis and asymmetric autocatalysis of chiral 5,5'-(3,3'-bipyridyl)-dialkanediol

(S,S)-(-)-5,5'-(3,3'-Bipyridyl)dialkanediols (5a, b) with up to 98.6% e.e. was synthesized by the enantioselective addition of dialkylzincs to 3,3'-bipyridine-5,5'-dicarbaldehyde (4) using N,N-dipropylnorephedrine as a chiral catalyst. Chiral diol (5a) was found to work as an asymmetric autocatalyst in the enantioselective addition of diisopropylzinc to aldehyde (4).

SOLID FORMS OF 1-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDIN-5-YL)PYRIDIN-3-YL)-N,N-DIMETHYLMETHANAMINE

The present application relates to two crystalline polymorphic forms, crystalline methanol, ethanol and tetrahydrofuran solvates and a crystalline hydrate of the compound l-(5-(3-(7-(3-fluorophenyl)-3H- imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3- yl)-N,N-dimethylmethanamine (Ipivivint), to a pharmaceutical composition comprising them and their medical use for the treatment of disorders characterized by the activation of of the Wnt signaling pathway selected from cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, osteoarthritis and idiopathic pulmonary fibrosis. Also claimed is a process for the preparation of compounds of Formula (I) by reacting a starting material of Formula (A1) with a compound of Formula (A2).

A catalytic oxidation heterocyclic aromatic primary alcohol for the preparation of heterocyclic aromatic aldehyde

The invention provides a method for preparing heterocyclic aromatic aldehyde by catalytically oxidizing heterocyclic aromatic primary alcohol. The method takes dioxovanadium nitrate as a catalyst and air as an oxidant; under a normal pressure condition, the heterocyclic aromatic primary alcohol is high-selectively oxidized into the heterocyclic aromatic aldehyde. The method provided by the invention has a high oxidization yield and a byproduct is water, so that the method is green, economical and environment-friendly; reaction conditions are moderate and the operation is simple. A catalysis system takes the air as the oxidant and non-metal metal as a catalyst, reaction conditions are moderate and the oxidization efficiency is high; the catalysis system is green and economical and can be used for efficiently catalyzing the heterocyclic aromatic primary alcohol into the corresponding heterocyclic aromatic aldehyde. Compared with a noble metal catalysis system and a catalysis system containing nitrogen-oxygen free radicals, the catalysis system has low oxidization reaction cost and has very high application value.

Method for synthesizing 5-bromopyridine-3-formaldehyde

The invention belongs to the field of organic synthesis, and particularly relates to a method for synthesizing 5-bromopyridine-3-formaldehyde. In the method, 3,5-dibromopyridine is taken as a material, and tetramethylethylenediamine is taken as a stabilizer, so as to react with a Grignard reagent to prepare a product. The existence of tetramethylethylenediamine reduces the impurities in the product, and improves the yield; the synthesis method has a low requirement on the temperature, can be finished under the condition of 5 to 25 DEG C, saves energy consumption, and is easy to operate; in thesynthesis technology, a simple post-processing method has few steps and high yield, and is suitable for industrial production.

Reduction of Weinreb amides to aldehydes under ambient conditions with magnesium borohydride reagents Dedicated to the memory of Professor Sheldon Shore

Chloromagnesium dimethylaminoborohydride (ClMg+ [H3BNMe2]-, MgAB) is an analogue of the versatile lithium dialkylaminoborohydrides (LAB reagents), prepared by the reaction of dimethylamine-borane with methylmagnesium chloride. MgAB is a partial reducing agent for Weinreb amides under ambient conditions and is complementary to the commonly utilized lithium aluminum hydride (LiAlH4) and diisobutylaluminum hydride (DIBAL) reagents, while exhibiting enhanced chemoselectivity. To prevent over-reduction, the aldehyde products are readily isolated in good yields by forming the sodium bisulfite adducts. Aldehyde products can both be stored and later used as the bisulfite adducts, or can be regenerated from the bisulfite adducts by treatment with aqueous formaldehyde.

NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE

The present invention provides a nitrogen-containing heterocyclic compound or a pharmaceutically acceptable salt thereof having an inhibitory effect on the production of kynurenine, represented by formula (I): (wherein R6 and R7 may be the same or different and each represent a hydrogen atom or the like, R8, R9, R19, and R11 may be the same or different and each represent a hydrogen atom or the like, R1 represents lower alkyl which may be substituted with cycloalkyl, or the like, and R3 represents optionally substituted aryl or an optionally substituted heterocyclic group).

Synthesis of new 1-Aryl-4-(biarylmethylene)piperazine ligands, structurally related to adoprazine (SLV313)

A series of new 1-aryl-4-(biarylmethylene)piperazines has been synthesized. These ligands are structurally related to SLV-313, a potential atypical antipsychotic having potent D2 receptor antagonist and 5-HT 1A receptor agonist prope

Inhibitors of checkpoint kinases

The instant invention provides for compounds which comprise substituted triazoloquinazolinones that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by adminis

Novel potent and?selective αvβ3αvβ5 integrin dual antagonists with reduced binding affinity for?human serum albumin

The binding of lead compounds and drugs to human serum albumin (HSA) is a ubiquitous problem in drug discovery since it modulates the availability of the leads and drugs to their intended target, which is linked to biological efficacy. In our continuing e